Organization
Graduate Faculty of Interdisciplinary Research Faculty of Medicine University Hospital (Clinical Research Collaboration Promotion Department) Associate Professor
Title
Associate Professor
Kobayashi Motohiro
Education
-
Gifu Pharmaceutical University
1980.4 - 1982.1
Country： Japan
Course： Master course
Degree
-
博士（医学） ( 1992.3 岐阜大学 )
Papers
-
Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Reviewed
Anti-Cancer Drugs 18 905 - 911 2007.2
-
Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy. Reviewed
Cancer Sci 98 598 - 604 2007.1
-
Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. Reviewed
Anticancer Res 26 1145 - 1152 2006.3
-
Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. Reviewed
Cancer Sci 97 1410 - 1416 2006.2
-
Antitumor activity of TZT-1027 (Soblidotin). Reviewed
Anticancer Res. 2006 1973 - 1982 2006.1
-
Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secrting human lung cancer in vivo, a potent antitumor agent, with tubulin. Reviewed
Cancer Sci 94 826 - 833 2003.1
-
Introduction of apoptosis in human cancer cells by TZT-1027, an Characterization of the interaction of TZT-1027, an antimicrotubule agent. Reviewed
Apoptosis 5 345 - 353 2000.2
-
Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Reviewed
Jpn. J. Cancer Res.,(currently known as Cancer Sci) 88 737 - 747 2000.1
-
Antitumor activity of TZT-1027, a novel dolastatin 10 derivatives. Reviewed
Jpn. J. Cancer Res.,(currently known as Cancer Sci) 88 316 - 327 1997.1
-
オピオイド受容体のタイプ選択性に関する分子薬理学的研究 Reviewed
岐阜大学医学部紀要 39 ( 6 ) 541 - 558 1991.3
Presentations
-
Antitumor activity of TZT-1027, a tumor vascular targeting agents, and the role of p38 MAPK in its signal transduction International conference
15th AACR-NCI-EORTC International Conference on Molecular TageteS and Cancer Therapeutics 2003.1